norepinephrine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
sympathomimetic, phenethyl derivatives 1960 51-41-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • norepinephrine
  • (R)-Norepinephrine
  • arterenol
  • levarterenol
  • noradrenaline
  • norepinephrine bitartrate
  • (-)-noradrenaline
Precursor of epinephrine that is secreted by the ADRENAL MEDULLA and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers, and of the diffuse projection system in the brain that arises from the LOCUS CERULEUS. It is also found in plants and is used pharmacologically as a sympathomimetic.
  • Molecular weight: 169.18
  • Formula: C8H11NO3
  • CLOGP: -0.99
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 4
  • TPSA: 86.71
  • ALOGS: -1.13
  • ROTB: 2

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
6 mg P

ADMET properties:

PropertyValueReference
BA (Bioavailability) 3 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
July 13, 1950 FDA HOSPIRA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Multiple organ dysfunction syndrome 433.25 22.71 238 14352 55439 53279037
Septic shock 348.68 22.71 215 14375 62014 53272462
Hypotension 294.67 22.71 354 14236 253722 53080754
Cardiac arrest 290.88 22.71 225 14365 93442 53241034
Shock 269.78 22.71 130 14460 23009 53311467
Cardiogenic shock 262.32 22.71 117 14473 17365 53317111
Metabolic acidosis 165.82 22.71 117 14473 42125 53292351
Stress cardiomyopathy 160.20 22.71 67 14523 8495 53325981
Renal failure 151.59 22.71 174 14416 118278 53216198
Acute kidney injury 148.68 22.71 256 14334 253612 53080864
Fatigue 142.05 22.71 17 14573 730489 52603987
Intentional overdose 139.22 22.71 128 14462 67077 53267399
Peripheral ischaemia 136.85 22.71 51 14539 4768 53329708
Drug ineffective 133.76 22.71 506 14084 816739 52517737
Haemodynamic instability 130.40 22.71 58 14532 8536 53325940
Circulatory collapse 120.70 22.71 76 14514 22638 53311838
Lactic acidosis 116.48 22.71 90 14500 37163 53297313
Pulseless electrical activity 115.32 22.71 51 14539 7403 53327073
Toxicity to various agents 114.98 22.71 211 14379 219387 53115089
Vasoplegia syndrome 113.58 22.71 32 14558 1220 53333256
Respiratory failure 109.34 22.71 136 14454 100376 53234100
Propofol infusion syndrome 107.68 22.71 28 14562 784 53333692
Acute respiratory distress syndrome 104.18 22.71 70 14520 23262 53311214
Renal injury 101.49 22.71 51 14539 9853 53324623
Sepsis 99.39 22.71 158 14432 146271 53188205
Electrocardiogram QRS complex prolonged 94.38 22.71 41 14549 5701 53328775
Nausea 94.06 22.71 45 14545 756046 52578430
Bradycardia 88.45 22.71 103 14487 70953 53263523
Ventricular tachycardia 88.31 22.71 57 14533 17705 53316771
Headache 87.50 22.71 20 14570 536801 52797675
Pharyngeal haemorrhage 87.14 22.71 22 14568 546 53333930
Hyperlactacidaemia 85.35 22.71 31 14559 2694 53331782
Pulmonary oedema 84.40 22.71 88 14502 53635 53280841
Arthralgia 83.37 22.71 11 14579 439772 52894704
Dry gangrene 77.64 22.71 20 14570 539 53333937
Renal impairment 75.39 22.71 103 14487 83215 53251261
Myoglobin urine present 73.94 22.71 17 14573 280 53334196
Disseminated intravascular coagulation 73.59 22.71 53 14537 19666 53314810
Ventricular fibrillation 71.22 22.71 43 14547 11882 53322594
Extremity necrosis 70.61 22.71 24 14566 1715 53332761
Serotonin syndrome 68.07 22.71 57 14533 26349 53308127
Atrioventricular block first degree 67.98 22.71 34 14556 6501 53327975
Acidosis 65.26 22.71 40 14550 11352 53323124
Ventricular hypokinesia 61.27 22.71 28 14562 4384 53330092
Overdose 59.38 22.71 106 14484 107630 53226846
Electrocardiogram ST segment elevation 58.84 22.71 26 14564 3763 53330713
Fear 58.17 22.71 43 14547 16598 53317878
Fall 57.02 22.71 14 14576 358426 52976050
Tachycardia 56.49 22.71 104 14486 108108 53226368
Cardiomyopathy 54.95 22.71 42 14548 17046 53317430
Diabetes insipidus 54.31 22.71 22 14568 2569 53331907
Anuria 52.37 22.71 36 14554 12404 53322072
Pruritus 49.69 22.71 10 14580 293822 53040654
Dizziness 49.49 22.71 20 14570 372239 52962237
Drug hypersensitivity 49.32 22.71 7 14583 265235 53069241
Rash 48.83 22.71 31 14559 446160 52888316
Abdominal discomfort 48.56 22.71 3 14587 221059 53113417
Cardiotoxicity 47.97 22.71 28 14562 7271 53327205
Pain in extremity 47.58 22.71 10 14580 285040 53049436
Activated partial thromboplastin time prolonged 46.18 22.71 27 14563 7032 53327444
Hyperkalaemia 45.94 22.71 65 14525 54191 53280285
Alopecia 44.05 22.71 6 14584 234577 53099899
Systolic dysfunction 43.17 22.71 16 14574 1471 53333005
Anhedonia 42.81 22.71 30 14560 10657 53323819
Distributive shock 42.55 22.71 14 14576 904 53333572
Toxic encephalopathy 42.32 22.71 24 14566 5903 53328573
Coma 42.28 22.71 67 14523 61716 53272760
Blood pressure decreased 42.21 22.71 67 14523 61802 53272674
Weight decreased 41.85 22.71 7 14583 234941 53099535
Injury 40.14 22.71 59 14531 50912 53283564
Electrocardiogram QT prolonged 39.75 22.71 62 14528 56341 53278135
Drug intolerance 39.19 22.71 5 14585 205488 53128988
Weight increased 38.96 22.71 5 14585 204562 53129914
Hypoxia 38.95 22.71 61 14529 55619 53278857
Electrocardiogram ST segment depression 38.90 22.71 18 14572 2900 53331576
Nasopharyngitis 38.37 22.71 4 14586 192291 53142185
Diarrhoea 37.98 22.71 71 14519 625475 52709001
Coagulopathy 37.80 22.71 36 14554 19662 53314814
Reversible cerebral vasoconstriction syndrome 36.79 22.71 16 14574 2229 53332247
Hepatic failure 36.56 22.71 47 14543 35759 53298717
Unmasking of previously unidentified disease 35.77 22.71 12 14578 823 53333653
Cardio-respiratory arrest 35.18 22.71 60 14530 58698 53275778
Oliguria 34.85 22.71 25 14565 9213 53325263
Intestinal ischaemia 34.65 22.71 23 14567 7479 53326997
Ischaemic hepatitis 34.38 22.71 15 14575 2105 53332371
Acid base balance abnormal 34.27 22.71 9 14581 262 53334214
Malaise 33.71 22.71 29 14561 357588 52976888
Unevaluable event 32.93 22.71 53 14537 49445 53285031
Mydriasis 32.43 22.71 26 14564 11300 53323176
Insomnia 32.37 22.71 6 14584 187066 53147410
Renal tubular necrosis 32.24 22.71 26 14564 11393 53323083
Amylase increased 31.68 22.71 20 14570 5974 53328502
Alanine aminotransferase increased 31.59 22.71 76 14514 95019 53239457
Troponin increased 31.56 22.71 23 14567 8682 53325794
Swelling 31.26 22.71 7 14583 191098 53143378
Thrombocytopenia 31.18 22.71 96 14494 138631 53195845
Constipation 31.02 22.71 8 14582 198404 53136072
Back pain 30.42 22.71 13 14577 234234 53100242
Patent ductus arteriosus 30.28 22.71 17 14573 4101 53330375
Gait disturbance 29.95 22.71 4 14586 158838 53175638
Encephalopathy 29.54 22.71 43 14547 36765 53297711
Left ventricle outflow tract obstruction 29.41 22.71 8 14582 267 53334209
Diabetic macroangiopathy 29.40 22.71 7 14583 135 53334341
Altered state of consciousness 29.21 22.71 35 14555 24801 53309675
Supraventricular tachycardia 29.06 22.71 27 14563 14298 53320178
Pain 28.92 22.71 75 14515 588323 52746153
Hypersensitivity 28.47 22.71 11 14579 210654 53123822
Haemodialysis 27.81 22.71 22 14568 9382 53325094
Torsade de pointes 27.32 22.71 25 14565 12980 53321496
Local anaesthetic systemic toxicity 27.27 22.71 9 14581 587 53333889
Infusion related reaction 26.98 22.71 5 14585 155952 53178524
Electrocardiogram repolarisation abnormality 26.84 22.71 11 14579 1323 53333153
Suicide attempt 26.74 22.71 53 14537 58115 53276361
Muscle spasms 26.38 22.71 3 14587 134792 53199684
Cardiovascular insufficiency 26.28 22.71 11 14579 1395 53333081
Cardiopulmonary failure 26.27 22.71 15 14575 3736 53330740
Acute coronary syndrome 25.82 22.71 22 14568 10402 53324074
Pseudomonas infection 25.81 22.71 22 14568 10406 53324070
Dyspnoea 25.64 22.71 79 14511 586153 52748323
Ventricular extrasystoles 25.54 22.71 23 14567 11701 53322775
Blood pressure increased 25.41 22.71 4 14586 140475 53194001
Cough 25.21 22.71 20 14570 256873 53077603
Sinus bradycardia 24.87 22.71 25 14565 14576 53319900
Emotional distress 24.84 22.71 37 14553 32280 53302196
Premature delivery 24.68 22.71 33 14557 26071 53308405
Polyserositis 24.54 22.71 7 14583 279 53334197
Wrong product administered 24.27 22.71 17 14573 6031 53328445
Contraindicated product administered 24.22 22.71 4 14586 135625 53198851
Feeling abnormal 24.14 22.71 4 14586 135297 53199179
Vasoconstriction 24.09 22.71 8 14582 532 53333944
Therapeutic product effect decreased 24.08 22.71 3 14587 125652 53208824
Drug ineffective for unapproved indication 24.03 22.71 29 14561 20691 53313785
Myalgia 23.70 22.71 4 14586 133487 53200989
Central nervous system injury 23.65 22.71 6 14584 152 53334324
Abdominal pain upper 23.62 22.71 8 14582 166283 53168193
Arteriospasm coronary 23.53 22.71 14 14576 3763 53330713
Blood creatine phosphokinase increased 23.46 22.71 34 14556 28951 53305525
Hypothermia 23.43 22.71 23 14567 13033 53321443
Hyperdynamic left ventricle 23.28 22.71 6 14584 162 53334314
Erythema 23.28 22.71 7 14583 156962 53177514
Ischaemia 23.12 22.71 15 14575 4693 53329783
Abdominal sepsis 22.90 22.71 10 14580 1406 53333070
Tuberculosis gastrointestinal 22.78 22.71 7 14583 362 53334114

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Multiple organ dysfunction syndrome 522.10 20.16 370 16857 69484 32426815
Cardiogenic shock 321.77 20.16 175 17052 20487 32475812
Septic shock 276.33 20.16 254 16973 68735 32427564
Drug ineffective 260.87 20.16 603 16624 382874 32113425
Appendicolith 193.02 20.16 70 17157 3095 32493204
Shock 180.13 20.16 128 17099 23986 32472313
Stress 167.92 20.16 122 17105 23660 32472639
Hypotension 164.03 20.16 356 16871 215754 32280545
Cardiac arrest 149.59 20.16 218 17009 96558 32399741
Haemodynamic instability 140.85 20.16 76 17151 8735 32487564
Sepsis 132.28 20.16 272 16955 158562 32337737
Appendicitis 128.83 20.16 72 17155 8865 32487434
Acute respiratory distress syndrome 122.88 20.16 104 17123 25149 32471150
Fear 120.60 20.16 75 17152 11244 32485055
Respiratory failure 116.88 20.16 206 17021 106976 32389323
Propofol infusion syndrome 115.87 20.16 35 17192 865 32495434
Metabolic acidosis 114.78 20.16 124 17103 40575 32455724
Acute kidney injury 114.73 20.16 378 16849 293090 32203209
Toxic epidermal necrolysis 104.70 20.16 87 17140 20506 32475793
Fatigue 103.67 20.16 29 17198 350672 32145627
Renal failure 97.67 20.16 218 17009 134260 32362039
Injury 90.94 20.16 83 17144 22162 32474137
Rhabdomyolysis 90.27 20.16 142 17085 67123 32429176
Off label use 86.24 20.16 355 16872 305965 32190334
Renal injury 85.39 20.16 62 17165 11993 32484306
Ventricular fibrillation 83.59 20.16 71 17156 17239 32479060
Anhedonia 79.98 20.16 52 17175 8412 32487887
Dizziness 77.29 20.16 10 17217 209608 32286691
Lactic acidosis 77.21 20.16 92 17135 33444 32462855
Headache 75.71 20.16 8 17219 196189 32300110
Emotional distress 72.89 20.16 64 17163 16242 32480057
Asthenia 70.55 20.16 19 17208 235925 32260374
Diarrhoea 68.47 20.16 56 17171 364746 32131553
Weight decreased 68.22 20.16 5 17222 164813 32331486
Vasoplegia syndrome 66.28 20.16 26 17201 1428 32494871
Stress cardiomyopathy 61.11 20.16 26 17201 1760 32494539
Ascites 58.29 20.16 88 17139 40103 32456196
Unevaluable event 55.17 20.16 78 17149 33508 32462791
Drug ineffective for unapproved indication 55.07 20.16 51 17176 13861 32482438
Arthralgia 54.87 20.16 7 17220 148441 32347858
Acidosis 53.40 20.16 45 17182 10801 32485498
Dry gangrene 52.56 20.16 16 17211 406 32495893
Myocardial calcification 51.10 20.16 10 17217 32 32496267
Pain in extremity 50.97 20.16 3 17224 118898 32377401
Bradycardia 50.69 20.16 115 17112 71447 32424852
Hypertransaminasaemia 50.46 20.16 30 17197 4144 32492155
Fall 49.57 20.16 21 17206 196180 32300119
Coma 47.74 20.16 83 17144 42529 32453770
Dyspnoea 46.79 20.16 75 17152 361970 32134329
Renal impairment 46.48 20.16 130 17097 91842 32404457
Decreased appetite 44.29 20.16 15 17212 160798 32335501
Activated partial thromboplastin time prolonged 43.53 20.16 36 17191 8419 32487880
Anion gap 43.45 20.16 16 17211 738 32495561
Electrocardiogram QRS complex prolonged 42.96 20.16 28 17199 4546 32491753
Coagulopathy 42.25 20.16 52 17175 19525 32476774
Back pain 41.60 20.16 5 17222 111048 32385251
Pharyngeal haemorrhage 40.20 20.16 15 17212 718 32495581
Malaise 40.09 20.16 22 17205 177116 32319183
Pulseless electrical activity 39.14 20.16 31 17196 6819 32489480
Diabetes insipidus 37.36 20.16 21 17206 2611 32493688
Ventricular tachycardia 37.09 20.16 56 17171 25500 32470799
Abdominal distension 36.93 20.16 83 17144 51212 32445087
Pruritus 35.44 20.16 12 17215 128690 32367609
Intestinal ischaemia 35.38 20.16 30 17197 7261 32489038
COVID-19 pneumonia 34.57 20.16 32 17195 8688 32487611
Rash 34.57 20.16 36 17191 209297 32287002
Disseminated intravascular coagulation 33.94 20.16 51 17176 23125 32473174
Heparin-induced thrombocytopenia 32.95 20.16 26 17201 5688 32490611
Torsade de pointes 32.92 20.16 29 17198 7386 32488913
Thrombocytopenia 32.55 20.16 160 17067 148139 32348160
Overdose 30.96 20.16 109 17118 86968 32409331
Drug reaction with eosinophilia and systemic symptoms 30.95 20.16 59 17168 32426 32463873
Oliguria 30.31 20.16 29 17198 8205 32488094
Blood pressure decreased 29.61 20.16 76 17151 51004 32445295
Gait disturbance 29.18 20.16 4 17223 80404 32415895
Dehydration 29.18 20.16 16 17211 128942 32367357
Toxicity to various agents 28.92 20.16 177 17050 177864 32318435
Peripheral ischaemia 28.38 20.16 24 17203 5787 32490512
Hyperdynamic left ventricle 27.38 20.16 7 17220 91 32496208
Electrocardiogram QT prolonged 27.26 20.16 63 17164 39578 32456721
Compartment syndrome 27.24 20.16 17 17210 2560 32493739
Catheter site haemorrhage 26.58 20.16 16 17211 2259 32494040
Insomnia 26.51 20.16 10 17217 100338 32395961
General physical health deterioration 26.45 20.16 126 17101 115133 32381166
Hypercapnia 26.43 20.16 20 17207 4115 32492184
Tachycardia 26.41 20.16 97 17130 78991 32417308
Cardiovascular insufficiency 26.23 20.16 14 17213 1572 32494727
Symmetrical drug-related intertriginous and flexural exanthema 25.50 20.16 8 17219 225 32496074
Hyponatraemia 25.39 20.16 92 17135 74421 32421878
Serotonin syndrome 25.09 20.16 40 17187 19077 32477222
Chest pain 24.51 20.16 18 17209 124119 32372180
Cholangiolitis 24.12 20.16 5 17222 23 32496276
Cough 23.89 20.16 23 17204 138794 32357505
Burkholderia test positive 23.75 20.16 9 17218 450 32495849
Intra-abdominal fluid collection 23.40 20.16 12 17215 1241 32495058
Pneumatosis intestinalis 22.88 20.16 17 17210 3403 32492896
Oesophageal ulcer haemorrhage 22.83 20.16 7 17220 182 32496117
Hypoxia 22.77 20.16 70 17157 52062 32444237
Pneumonia acinetobacter 22.67 20.16 6 17221 90 32496209
Laryngomalacia 22.58 20.16 8 17219 330 32495969
COVID-19 22.14 20.16 51 17176 31964 32464335
Mean arterial pressure increased 22.13 20.16 4 17223 7 32496292
Post procedural haemorrhage 21.14 20.16 24 17203 8276 32488023
Pulse absent 20.88 20.16 20 17207 5666 32490633
Product use in unapproved indication 20.48 20.16 96 17131 87108 32409191
Malignant neoplasm progression 20.44 20.16 8 17219 78488 32417811
Liver function test increased 20.36 20.16 29 17198 12531 32483768
Herpes zoster reactivation 20.28 20.16 7 17220 267 32496032

Pharmacologic Action:

SourceCodeDescription
ATC C01CA03 CARDIOVASCULAR SYSTEM
CARDIAC THERAPY
CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES
Adrenergic and dopaminergic agents
FDA CS M0003647 Catecholamines
FDA EPC N0000175570 Catecholamine
MeSH PA D018663 Adrenergic Agents
MeSH PA D000322 Adrenergic Agonists
MeSH PA D000316 Adrenergic alpha-Agonists
MeSH PA D002317 Cardiovascular Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D013566 Sympathomimetics
MeSH PA D014662 Vasoconstrictor Agents
CHEBI has role CHEBI:25512 neurotransmitters
CHEBI has role CHEBI:35524 sympathomimetic
CHEBI has role CHEBI:35569 alpha-adrenergic receptor agonist
CHEBI has role CHEBI:75771 Mus musculus metabolite
CHEBI has role CHEBI:76967 human xenobiotic metabolites

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Bronchiectasis indication 12295008 DOID:9563
Bronchitis indication 32398004 DOID:6132
Low blood pressure indication 45007003
Pulmonary emphysema indication 87433001
Asthma indication 195967001 DOID:2841
Asthma management indication 406162001
Acute exacerbation of asthma indication 708038006
Hypovolemia contraindication 28560003
Hypercapnia contraindication 29596007
Hypertensive disorder contraindication 38341003 DOID:10763
Hypoxia contraindication 389086002
Thrombosis contraindication 439127006
Occlusive Vascular Disease contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.41 acidic
pKa2 12.03 acidic
pKa3 12.63 acidic
pKa4 8.83 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Alpha-2C adrenergic receptor GPCR AGONIST Ki 7.20 CHEMBL CHEMBL
Alpha-1A adrenergic receptor GPCR AGONIST Ki 5.82 CHEMBL CHEMBL
Alpha-1D adrenergic receptor GPCR AGONIST Ki 7.40 IUPHAR CHEMBL
Alpha-1B adrenergic receptor GPCR AGONIST Ki 4.69 CHEMBL CHEMBL
Beta-2 adrenergic receptor GPCR AGONIST Kd 5.40 CHEMBL CHEMBL
Alpha-2A adrenergic receptor GPCR AGONIST Ki 7.18 CHEMBL CHEMBL
Beta-1 adrenergic receptor GPCR AGONIST Ki 6 IUPHAR CHEMBL
D(1A) dopamine receptor GPCR Kd 4.30 CHEMBL
D(2) dopamine receptor GPCR Ki 5.89 CHEMBL
Alpha-2B adrenergic receptor GPCR Ki 6.48 PDSP
Beta-3 adrenergic receptor GPCR Ki 5.37 PDSP
Sodium-dependent dopamine transporter Transporter Ki 5.07 PDSP
Mu-type opioid receptor GPCR Ki 4.85 CHEMBL
Beta-2 adrenergic receptor GPCR Ki 5.22 CHEMBL
Beta-1 adrenergic receptor GPCR Ki 6.90 CHEMBL
Beta-2 adrenergic receptor GPCR Ki 5.30 CHEMBL
Alpha-1A adrenergic receptor GPCR Ki 6.35 CHEMBL
Beta-2 adrenergic receptor GPCR Ki 5.38 CHEMBL
Alpha-1B adrenergic receptor GPCR Ki 6.58 CHEMBL
Beta-1 adrenergic receptor GPCR Ki 6.40 CHEMBL
Adrenergic receptor alpha-2 GPCR Ki 8.32 CHEMBL
Adrenergic receptor alpha-1 GPCR Ki 6.41 CHEMBL
Adrenergic receptor alpha GPCR IC50 7.80 CHEMBL
Adrenergic receptor beta GPCR IC50 6 CHEMBL
Alpha-2C adrenergic receptor GPCR Ki 6.19 CHEMBL
Alpha-2A adrenergic receptor GPCR Ki 5.24 CHEMBL
Alpha-2B adrenergic receptor GPCR Ki 7.11 CHEMBL

External reference:

IDSource
4019859 VUID
N0000147945 NUI
D00076 KEGG_DRUG
108341-18-0 SECONDARY_CAS_RN
4018242 VANDF
4019859 VANDF
C0028351 UMLSCUI
CHEBI:33569 CHEBI
E5E PDB_CHEM_ID
CHEMBL1434513 ChEMBL_ID
CHEMBL1437 ChEMBL_ID
DB00368 DRUGBANK_ID
CHEMBL1356607 ChEMBL_ID
D009638 MESH_DESCRIPTOR_UI
439260 PUBCHEM_CID
33 INN_ID
484 IUPHAR_LIGAND_ID
X4W3ENH1CV UNII
7508 RXNORM
2706 MMSL
333906 MMSL
35060 MMSL
5186 MMSL
NOCODE MMSL
d00323 MMSL
001777 NDDF
004718 NDDF
111130009 SNOMEDCT_US
45555007 SNOMEDCT_US
77673009 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Norepinephrine Bitartrate HUMAN PRESCRIPTION DRUG LABEL 1 0143-9318 INJECTION 1 mg INTRAVENOUS ANDA 24 sections
NOREPINEPHRINE BITARTRATE HUMAN PRESCRIPTION DRUG LABEL 1 0338-0108 INJECTION, SOLUTION 8 mg INTRAVENOUS NDA 24 sections
NOREPINEPHRINE BITARTRATE HUMAN PRESCRIPTION DRUG LABEL 1 0338-0112 INJECTION, SOLUTION 4 mg INTRAVENOUS NDA 24 sections
Levophed HUMAN PRESCRIPTION DRUG LABEL 1 0409-1443 INJECTION, SOLUTION, CONCENTRATE 1 mg INTRAVENOUS NDA 20 sections
Levophed HUMAN PRESCRIPTION DRUG LABEL 1 0409-1443 INJECTION, SOLUTION, CONCENTRATE 1 mg INTRAVENOUS NDA 20 sections
LEVOPHED Human prescription drug label 1 0409-3375 INJECTION, SOLUTION, CONCENTRATE 1 mg INTRAVENOUS NDA 27 sections
LEVOPHED Human prescription drug label 1 0409-3375 INJECTION, SOLUTION, CONCENTRATE 1 mg INTRAVENOUS NDA 27 sections
Norepinephrine Bitartrate HUMAN PRESCRIPTION DRUG LABEL 1 0703-1153 INJECTION, SOLUTION, CONCENTRATE 1 mg INTRAVENOUS ANDA 24 sections
Norepinephrine Bitartrate HUMAN PRESCRIPTION DRUG LABEL 1 0703-1153 INJECTION, SOLUTION, CONCENTRATE 1 mg INTRAVENOUS ANDA 24 sections
NOREPINEPHRINE BITARTRATE HUMAN PRESCRIPTION DRUG LABEL 1 0781-3755 INJECTION, SOLUTION, CONCENTRATE 1 mg INTRAVENOUS ANDA 24 sections
Norepinephrine Bitartrate HUMAN PRESCRIPTION DRUG LABEL 1 25021-316 INJECTION, SOLUTION 1 mg INTRAVENOUS ANDA 25 sections
Norepinephrine bitartrate HUMAN PRESCRIPTION DRUG LABEL 1 36000-162 INJECTION 1 mg INTRAVENOUS ANDA 18 sections
NOREPINEPHRINE BITARTRATE Human Prescription Drug Label 1 47335-615 INJECTION, SOLUTION, CONCENTRATE 1 mg INTRAVENOUS ANDA 24 sections
LEVOPHED(R) NOREPINEPHRINE BITARTRATE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1315 INJECTION, SOLUTION, CONCENTRATE 1 mg INTRAVENOUS NDA 12 sections
NOREPINEPHRINE BITARTRATE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1528 INJECTION 1 mg INTRAVENOUS ANDA 16 sections
Norepinephrine Bitartrate HUMAN PRESCRIPTION DRUG LABEL 1 51991-983 INJECTION, SOLUTION, CONCENTRATE 1 mg INTRAVENOUS ANDA 25 sections
Norepinephrine Bitartrate HUMAN PRESCRIPTION DRUG LABEL 1 52533-164 INJECTION, SOLUTION 64 ug INTRAVENOUS unapproved drug other 7 sections
Norepinephrine Bitartrate HUMAN PRESCRIPTION DRUG LABEL 1 52533-165 INJECTION, SOLUTION 16 ug INTRAVENOUS unapproved drug other 7 sections
Norepinephrine Bitartrate HUMAN PRESCRIPTION DRUG LABEL 1 52533-166 INJECTION, SOLUTION 32 ug INTRAVENOUS unapproved drug other 7 sections
Norepinephrine Bitartrate HUMAN PRESCRIPTION DRUG LABEL 1 63323-940 SOLUTION 1 mg INTRAVENOUS ANDA 24 sections
Norepinephrine bitartrate HUMAN PRESCRIPTION DRUG LABEL 1 67457-852 INJECTION, SOLUTION, CONCENTRATE 1 mg INTRAVENOUS ANDA 24 sections
Norepinephrine bitartrate Human Prescription Drug Label 1 68083-437 INJECTION 1 mg INTRAVENOUS ANDA 24 sections
Norepinephrine Bitartrate HUMAN PRESCRIPTION DRUG LABEL 1 70121-1576 INJECTION, SOLUTION, CONCENTRATE 1 mg INTRAVENOUS ANDA 18 sections
Norepinephrine bitartrate HUMAN PRESCRIPTION DRUG LABEL 1 72078-002 INJECTION, SOLUTION, CONCENTRATE 1 mg INTRAVENOUS ANDA 24 sections
NOREPINEPHRINE BITARTRATE HUMAN PRESCRIPTION DRUG LABEL 1 72572-481 INJECTION, SOLUTION, CONCENTRATE 1 mg INTRAVENOUS ANDA 24 sections